Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) – (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announces that, it has applied and received conditional approval to list the Company’s common shares (the “Shares“) for trading on the TSX Venture Exchange (the “TSXV“) as a Tier 2 Life Science Issuer. Final approval of the listing on the TSXV is subject to the Company satisfying certain conditions required by the TSXV. The Company’s management team is working diligently to satisfy such listing conditions. Subject to the receipt of TSXV’s final approval of listing, the Company expects a seamless transition from trading on the Toronto Stock Exchange (the “TSX“) to the TSXV. Upon listing on the TSXV, the Company…